Cordis

Executive Summary

Cordis is a global leader in cardiovascular and endovascular medical devices, with a 60+ year history of pioneering minimally invasive technologies. The company's portfolio includes stents, balloons, catheters, and guidewires for coronary and peripheral artery disease. As a private company, Cordis benefits from long-term strategic focus without quarterly earnings pressure, enabling sustained investment in innovation. Recent developments include the launch of next-generation drug-eluting stents and expansion into emerging markets, which are expected to drive growth. However, the competitive landscape remains intense with players like Abbott and Boston Scientific. Cordis's strong brand and distribution network position it well to capture market share, though revenue growth may be moderate given market maturity.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for new peripheral drug-eluting stent75% success
• Q2 2026Expansion into Asia-Pacific markets with local partnerships80% success
• Q4 2026Positive 2-year clinical data for coronary balloon catheter70% success